Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2007
The article in the October 2006 issue of the ARCHIVES by ElHassan and colleagues1 concludes that respiratory syncytial virus (RSV) prophylaxis with palivizumab is not cost-effective, and therefore its use should be restricted. While this study includes the effects of asthma sequelae from RSV infection, readers need to appreciate that 2 key assumptions in the paper are controversial and strongly influence the results.
Mahadevia PJ, Malinoski FJ. Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis With Palivizumab. Arch Pediatr Adolesc Med. 2007;161(5):519-520. doi:10.1001/archpedi.161.5.519